Atara Biotherapeutics, Inc.

LSE:0HIY Stock Report

Market Cap: US$66.1m

Atara Biotherapeutics Valuation

Is 0HIY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HIY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HIY ($12.02) is trading below our estimate of fair value ($57.61)

Significantly Below Fair Value: 0HIY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HIY?

Key metric: As 0HIY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HIY. This is calculated by dividing 0HIY's market cap by their current revenue.
What is 0HIY's PS Ratio?
PS Ratio0.7x
SalesUS$100.44m
Market CapUS$66.06m

Price to Sales Ratio vs Peers

How does 0HIY's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HIY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.7x
TRX Tissue Regenix Group
1.6x15.1%UK£40.6m
AREC Arecor Therapeutics
5.9x35.2%UK£28.3m
BVXP Bioventix
14.4xn/aUK£195.7m
PBX ProBiotix Health
5xn/aUK£10.7m
0HIY Atara Biotherapeutics
0.7x9.7%US$66.1m

Price-To-Sales vs Peers: 0HIY is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (6.7x).

Price to Sales Ratio vs Industry

How does 0HIY's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.0x19.6%
0HIY Atara Biotherapeutics
 0.7x9.7%US$66.06m
GNS Genus
1.7x3.5%US$1.39b
OXB Oxford Biomedica
4.6x21.0%US$561.36m
0HIY 0.7xIndustry Avg. 8.0xNo. of Companies8PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.0x37.0%
0HIY Atara Biotherapeutics
 0.7x36.7%US$66.06m
No more companies

Price-To-Sales vs Industry: 0HIY is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 0HIY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HIY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: 0HIY is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HIY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.84
US$14.75
+24.6%
33.0%US$21.00US$10.00n/a4
Nov ’25US$9.74
US$150.50
+1,445.2%
92.7%US$325.00US$9.00n/a4
Oct ’25US$7.57
US$150.50
+1,888.1%
92.7%US$325.00US$9.00n/a4
Sep ’25US$7.58
US$150.50
+1,885.8%
92.7%US$325.00US$9.00n/a4
Aug ’25US$9.85
US$104.00
+956.4%
123.6%US$325.00US$11.00n/a4
Jul ’25US$8.42
US$104.38
+1,140.3%
122.9%US$325.00US$12.50n/a4
Jun ’25US$13.76
US$104.38
+658.8%
122.9%US$325.00US$12.50n/a4
May ’25US$18.75
US$105.00
+460.0%
122.0%US$325.00US$12.50n/a4
Apr ’25US$17.37
US$105.00
+504.7%
122.0%US$325.00US$12.50n/a4
Mar ’25US$19.67
US$120.63
+513.2%
103.7%US$325.00US$12.50n/a4
Feb ’25US$18.70
US$120.63
+545.1%
103.7%US$325.00US$12.50n/a4
Jan ’25US$14.57
US$120.63
+728.2%
103.7%US$325.00US$12.50n/a4
Dec ’24US$15.88
US$98.50
+520.5%
122.2%US$325.00US$10.00n/a5
Nov ’24US$32.25
US$363.33
+1,026.6%
83.0%US$775.00US$35.00US$9.746
Oct ’24US$36.74
US$367.92
+901.5%
82.3%US$775.00US$35.00US$7.576
Sep ’24US$38.99
US$367.92
+843.7%
82.3%US$775.00US$35.00US$7.586
Aug ’24US$54.63
US$406.79
+644.7%
71.7%US$775.00US$50.00US$9.857
Jul ’24US$39.05
US$406.79
+941.7%
71.7%US$775.00US$50.00US$8.427
Jun ’24US$38.50
US$403.21
+947.3%
71.5%US$775.00US$50.00US$13.767
May ’24US$68.45
US$462.50
+575.7%
88.4%US$1,250.00US$50.00US$18.758
Apr ’24US$74.01
US$462.50
+524.9%
88.4%US$1,250.00US$50.00US$17.378
Mar ’24US$96.20
US$462.50
+380.8%
88.4%US$1,250.00US$50.00US$19.678
Feb ’24US$126.13
US$471.88
+274.1%
86.7%US$1,250.00US$75.00US$18.708
Jan ’24US$80.63
US$450.00
+458.1%
96.3%US$1,250.00US$75.00US$14.577
Dec ’23US$109.26
US$468.75
+329.0%
87.1%US$1,250.00US$75.00US$15.888
Nov ’23US$124.01
US$469.69
+278.7%
86.8%US$1,250.00US$75.00US$32.258

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%